Appeals court revives $6.7B lawsuit against Bristol Myers over delayed drug approvals, adding legal overhang.

What happened

A U.S. appeals court revived a $6.7B lawsuit accusing Bristol Myers Squibb of cheating former Celgene shareholders by delaying federal approval for three drugs, including the cancer treatment Breyanzi, to avoid milestone payments tied to the 2019 acquisition. The ruling reverses a lower court's dismissal, meaning the case will proceed to discovery and potentially trial, adding a long-tail legal overhang that was previously discounted. Management's recent 10-K discusses litigation contingencies but does not quantify this specific revived claim, suggesting it was not considered a probable loss. The revived lawsuit does not change the immediate operating trajectory—Eliquis remains subject to IRA price resets and Revlimid faces an erosion inflection on January 31, 2026—but it adds a new source of headline risk and potential cash outflow. Net-net, the legal development reinforces the WAIT rating by increasing left-tail uncertainty without altering the core bridge-year thesis around gross margin and Eliquis volume.

Implication

Investors should view the revived lawsuit as a genuine tail risk that adds uncertainty but is unlikely to be resolved in the next 12 months, given typical litigation timelines. The $6.7B claim is material relative to BMY's ~$123B market cap, but securities class actions of this nature often settle for a fraction of claimed damages. Near term, the more important catalysts remain Eliquis volume defense and gross margin stability, which will determine whether the bridge year holds. Any indication in upcoming 10-Q filings of a litigation reserve or settlement discussions would be a negative signal for near-term earnings. We recommend maintaining positions at current levels but avoiding adding until there is more clarity on both the legal front and the fundamental scorecard.

Thesis delta

The core thesis remains unchanged: BMY is a WAIT awaiting confirmation that Eliquis can grow 10-15% in 2026 while holding gross margin at 69-70%. However, the revived Celgene-related lawsuit increases the probability of an adverse legal outcome that is not fully reflected in current guidance or valuation. We slightly lower conviction from 3.5 to 3.0 due to this added tail risk, while keeping the $52 bear case.